Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mereo BioPharma

Celgene building

BMS and Celgene announce $74bn merger

Huge news for sector, with new fourth-placed company to be created

- PMLiVE

Ex-Pharmacyclics CEO invests $25m in Summit

After Duchenne drug failure, UK biotech looks to new anti-infective

- PMLiVE

Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

- PMLiVE

MedCity sets up advanced therapy research network

Aims to capitalise on UK's expertise in cutting-edge field

Celgene building

Celgene to launch five new products through to 2020

Two of which are CAR-T candidates

- PMLiVE

Orchard plans IPO as gene therapy pipeline advances

UK biotech seeks funds for expanded rare disease portfolio

- PMLiVE

DNA damage specialists Artios Pharma raises $84m

Team behind development of Lynparza focus on next-gen DDR inhibitors

- PMLiVE

Vernalis accepts £33m takeover offer from Ligand Pharma

Biotech buyout brings team of 70 scientists in Cambridge, UK

Celgene building

Celgene’s Revlimid gets a win in late-stage lymphoma

Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates

- PMLiVE

Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome ready to leap into future

A round-up from pharma, biotech and healthcare

- PMLiVE

Freeline raises £88m to accelerate haemophilia gene therapy

Spin-out from London university joins fast-developing field

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links